Armouring CAR-T Cells for Off-the-Shelf Therapeutics
Time: 12:30 pm
day: Day 2 - Track B - AM
Details:
- Utilising chRDNA genome-editing technology to engineer more precise genome edits
- Developing armouring strategies that improve antitumour response in allogeneic CAR-T cell therapies
- Reporting safety and efficacy dose escalation data from the ongoing CB-010 ANTLER Phase 1 trial
